We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
CIBINQO (Pfizer Australia Pty Ltd)
Product name
CIBINQO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
254 (255 working days)
Active ingredients
abrocitinib
Registration type
NCE/NBE
Indication
CIBINQO is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. CIBINQO can be used with or without medicated topical therapies for atopic dermatitis.